Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19677889 | 0.87 | DNM1 (0.48) | DNM1L3MBTL1 | |
| SCHEMBL5423731 | 0.86 | DNM1 (0.41) | DNM1KDM4EMAPK1TDP1HTR2A | |
| SCHEMBL25587775 | 0.85 | L3MBTL1 (0.39) | DNM1KDM4EMAPK1TDP1L3MBTL1 | |
| SCHEMBL5892049 | 0.83 | RAB9A (0.33) | DNM1KDM4EMAPK1TDP1ALDH1A1 | |
| SCHEMBL5408876 | 0.83 | DNM1 (0.48) | DNM1KDM4EMAPK1TDP1L3MBTL1 | |
| SCHEMBL5406861 | 0.83 | DNM1 (0.48) | DNM1KDM4EMAPK1TDP1L3MBTL1 | |
| SCHEMBL5414617 | 0.83 | DNM1 (0.48) | DNM1KDM4EMAPK1TDP1L3MBTL1 | |
| SCHEMBL5412524 | 0.83 | DNM1 (0.48) | DNM1KDM4EMAPK1TDP1L3MBTL1 | |
| SCHEMBL5412471 | 0.83 | DNM1 (0.48) | DNM1KDM4EMAPK1TDP1L3MBTL1 | |
| SCHEMBL5406792 | 0.83 | DNM1 (0.48) | DNM1KDM4EMAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | THE BROAD INSTITUTE, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240018552-A1 | NOVEL CRISPR ENZYMES AND SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-01-18 | — | — | US | disclosed |
| US-20160082126-A1 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN | UNIV TUFTS (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | KLRK1, CD47, FCGR3B | DNM1 3022/4885KDM4E 810/4885MAPK1 1799/4885 |
| US-20240018552-A1 | NOVEL CRISPR ENZYMES AND SYSTEMS | CPSF1, CPSF6, CPN1 | DNM1 3631/4885KDM4E 540/4885MAPK1 4861/4885 |
| US-20160082126-A1 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN | SARNP, SAP30BP, SCP2 | DNM1 3713/4885KDM4E 3977/4885MAPK1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.